By Tatiana Prowell, M.D. and Richard Pazdur, M.D. Researchers at an international oncology conference held in October in Spain reported that pertuzumab, which was FDA-approved for treatment of HER2+ metastatic breast cancer in June 2012, improved survival by an average of nearly 16 months when added to standard treatment. This was yet another piece of… Continue reading Getting Potentially Life-Saving Drugs to High-Risk Breast Cancer Patients Faster